Investors Research Corp lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,312 shares of the biopharmaceutical company’s stock after selling 2,075 shares during the quarter. Investors Research Corp’s holdings in Pfizer were worth $808,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Pfizer in the fourth quarter valued at $2,219,532,000. Morgan Stanley grew its holdings in Pfizer by 16.4% during the fourth quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after acquiring an additional 7,540,245 shares during the period. Bank of New York Mellon Corp grew its holdings in Pfizer by 12.1% during the fourth quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after acquiring an additional 6,965,496 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Pfizer during the fourth quarter worth about $162,707,000. Finally, Sanders Capital LLC increased its stake in Pfizer by 10.6% in the 4th quarter. Sanders Capital LLC now owns 31,947,816 shares of the biopharmaceutical company’s stock worth $1,280,997,000 after purchasing an additional 3,051,838 shares in the last quarter. 67.36% of the stock is owned by institutional investors and hedge funds.
PFE stock traded up $0.28 during midday trading on Tuesday, hitting $40.11. The stock had a trading volume of 1,051,295 shares, compared to its average volume of 31,749,029. The firm has a market cap of $223.72 billion, a PE ratio of 25.70, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.40 and a quick ratio of 1.13. Pfizer Inc. has a 12-month low of $31.61 and a 12-month high of $43.08. The company’s 50-day moving average price is $37.02 and its 200 day moving average price is $36.78.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The company had revenue of $11.68 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the previous year, the firm posted $0.55 EPS. Pfizer’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 4th. Shareholders of record on Friday, May 7th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 3.89%. The ex-dividend date is Thursday, May 6th. Pfizer’s payout ratio is 52.88%.
A number of equities analysts have commented on the company. Morgan Stanley reduced their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Friday, January 29th. SVB Leerink cut their target price on Pfizer from $40.00 to $39.00 and set a “market perform” rating on the stock in a research note on Thursday, April 1st. TheStreet downgraded Pfizer from a “b” rating to a “c+” rating in a report on Friday, March 5th. JPMorgan Chase & Co. set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, February 3rd. Finally, Berenberg Bank reissued a “neutral” rating and set a $38.00 price target on shares of Pfizer in a research report on Tuesday, March 23rd. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $38.47.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Read More: What is an Initial Coin Offering (ICO)?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.